GV backs new genomics R&D upstart; Vertex advances plans for next-gen CF drugs
GV — formerly known as Google Ventures — is joining a syndicate providing a $40 million Series A round to Dublin-based Genomics Medicine Ireland. The company …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.